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Abstract
The goal of the present study was to record changes in bone
mineral density (BMD) and markers of bone turnover in patients
with rheumatoid arthritis (RA) who were treated with
methotrexate combined (or not combined) with infliximab.
Included were 90 patients with RA who required anti-TNF-α
therapy with infliximab because of persistent active disease
despite treatment with methotrexate. The historical control
group included 99 patients with RA who were treated with
methotrexate at a time when anti-TNF-α treatment was not yet
available. Lumbar and femoral neck BMD was measured using
dual energy X-ray absorptiometry at baseline and 1 year later.
Osteocalcin, C-terminal cross-linked telopeptide of type I
collagen, parathyroid hormone and 25-hydroxycholecalciferol
were measured in plasma at baseline and 1 year later. At 1 year
BMD had decreased in the control group at spine (P < 0.01)
and femoral neck (P < 0.001). In contrast, BMD at spine and
femoral neck did not change after 1 year of infliximab treatment.
At the same time point, no change in bone remodelling markers
was observed. No association was observed between clinical
response and changes in BMD, indicating that even those who
did not respond clinically did not lose bone over a 1-year period.
These data confirm the BMD decrease observed in RA patients
treated with methotrexate alone. This bone loss was prevented
by infliximab therapy. Importantly, this beneficial effect was also
observed in apparent nonresponders.
Introduction
Rheumatoid arthritis (RA) is a chronic disease that is charac-
terized by joint inflammation and local bone erosion. In addi-
tion, generalized bone loss has been demonstrated in RA
patients [1,2]. This could be due to the disease itself, to
reduced exercise activity, or to treatment with steroids [3], but
it could also result from common postmenopausal
osteoporosis.
Among the factors that can influence bone resorption and
osteoclast activity, tumour necrosis factor (TNF)-α plays a cen-
tral role in the destructive process of RA and has been shown
to increase bone resorption in systemic osteoporosis related
to oestrogen deficiency [4]. In transgenic mice expressing sol-
uble TNF receptor to neutralize TNF-α, animals were pro-
tected from oestrogen deficiency-related bone loss [5]. TNF-α
is also a powerful inhibitor of bone formation [6].
Infliximab is a neutralizing chimeric monoclonal anti-TNF-α
antibody that has been successfully used in RA treatment [7],
and has an effect on joint destruction [8]. However, its sys-
temic effect on bone remains to be elucidated. In this study,
we compared bone mineral density (BMD) values between RA
patients treated with infliximab and those not receiving inflixi-
mab. Previous open studies have demonstrated either an
BMD = bone mineral density; CTX-I = C-terminal cross-linking telopeptide of type I collagen; DAS = Disease Activity Score; 25-OHD = 25-hydrox-
ycholecalciferol; PTH = parathyroid hormone; RA = rheumatoid arthritis; SD = standard deviation; sRANKL = soluble receptor activator of nuclear 
factor-kB ligand; TNF = tumour necrosis factor.Arthritis Research & Therapy    Vol 9 No 3    Marotte et al.
Page 2 of 7
(page number not for citation purposes)
increase in BMD or no change. A major limitation of these
studies is that they did not include a control group [9,10]. The
optimal design for this type of study would be a double-blind
randomized comparison with placebo. However, because
TNF-α blockers are now on the market, ethical issues would
prevent such a randomized, placebo-controlled trial. Another
option is to perform a historical control study, with controls
being active RA patients followed before the advent of TNF-α
blocker therapy and who were treated with methotrexate
alone. Such a historical control group is of great interest
because it is not influenced by use of TNF inhibitors in patients
with the most active disease.
This case-control study was conducted to compare changes
in BMD between RA patients treated with infliximab and those
not receiving this agent over 1 year. Moreover, we investigated
bone turnover using biochemical markers of bone formation
and resorption, and we studied the relationship between
changes in BMD and clinical response to therapy.
Materials and methods
Patients
All patients fulfilled the American College of Rheumatology cri-
teria for RA [11] and gave informed consent to participate in
this study, which was approved by the ethics committee. This
study was performed by the investigators, independent of and
unsupported by Centocor or Schering-Plough.
The control group included 99 patients (21 men and 78
women) who were consecutively enrolled before the advent of
anti-TNF-α treatment, from 1996 to 2000. All of them were
receiving methotrexate. The infliximab-treated group included
90 patients (16 men and 74 women) requiring anti-TNF-α
therapy for treatment of persistent active disease, despite
treatment with methotrexate. Patients were enrolled, starting
from when infliximab entered the market, from January 2001 to
October 2003. Infliximab was administrated at 3 mg/kg on
weeks 0, 2 and 6, and then every 8 weeks combined with
methotrexate (in accordance with the ATTRACT [Anti-TNF
Therapy in RA with Concomitant Therapy] protocol [7]). All of
these patients were included in the study and followed over 1
year.
RA activity was evaluated using the Disease Activity Score
(DAS)28 [12], and a good clinical response was defined as an
improvement of at least 1.2 in DAS28 score at 1 year.
Bone mineral density evaluation
At baseline and 1 year later, BMD (g/cm2) was determined at
the lumbar spine (first to fourth vertebrae, antero-posterior
view) and at the right femoral neck, by dual-energy X ray
absorptiometry using a QDR 4500 device (Hologic, Waltham,
MA, USA). Quality control for the device was performed by
daily assessment of a spine phantom. The in vivo precision
error for dual-energy X ray absorptiometry, expressed as a
coefficient of variation, was 0.9% at the lumbar spine and 1%
at the femoral neck.
T scores (number of standard deviations [SDs]) from control
individuals were calculated, in accordance with published ref-
erence values obtained in sex-matched control individuals
studied using the same equipment at the same institution [13].
Osteopenia was defined as a T score between -1 and -2.5 SD
and osteoporosis as a T score of -2.5 SD or less.
Markers of bone turnover
All bone markers were measured using commercial assays, in
accordance with instructions of the manufacturers. Osteocal-
cin (normal values 15 to 46 ng/ml), C-terminal cross-linking
telopeptide of type I collagen (CTX-I; 330 to 782 pg/ml) and
parathyroid hormone (PTH; 15 to 65 pg/ml) were measured
using an Elecsys 2010 (Roche Diagnostics, Mannheim, Ger-
many), and 25-hydroxycholecalciferol (25-OHD; 12 to 40 ng/
ml) was measured using a radioimmunoassay (Incstar, Stillwa-
ter, MN, USA).
Statistical analysis
Changes were compared between values at entry and at 1
year for BMD, DAS28, osteocalcin, CTX-I, PTH, 25-OHD,
erythrocyte sedimentation rate and C-reactive protein. Data for
both groups were compared using the unpaired Student's t-
test for continuous variables. In each group, data were com-
pared using the Student's paired t-test for continuous varia-
bles, between baseline and 1 year later. Absolute changes
were measured and presented as variation, defined as the final
values minus the initial values. BMD variation was also repre-
sented as relative (%) changes. Correlations between
changes in BMD and in biochemical parameters were tested
using the Pearson correlation coefficient. Several analysis of
covariance models for BMD variations (final values minus initial
values) were built to analyze the effect of cofactors (continu-
ous variables and discrete variables) on that of infliximab. All
analyses were performed with SPSS (SPSS Institute, Cary,
NC, USA) software.
Results
Control and infliximab group characteristics at baseline
Demographic, clinical, biological and BMD characteristics of
the 189 RA patients enrolled in the study are summarized in
Table 1. Patients exhibited typical clinical and biological fea-
tures of RA. The study included 152 women and 37 men
(mean ± SD age 52.5 ± 14.2 years). The disease duration was
10.6 ± 9.0 years. A total of 118 patients (62%) were on ster-
oids (mean dose 5.30 ± 5.79 mg/day). The DAS28 score was
5.17 ± 1.07. Thirty-five patients (19%) were on biphospho-
nates. At baseline, serum PTH and 25-OHD levels were 30.5
± 17.6 pg/ml and 19.7 ± 10.3 ng/ml, respectively. Serum
osteocalcin and serum CTX-I were 19.9 ± 11.8 ng/ml and 446
± 307 pg/ml, respectively. All of these values were in the nor-
mal range. The femoral neck and lumbar BMD values wereAvailable online http://arthritis-research.com/content/9/3/R61
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0.801 ± 0.159 g/cm2 and 0.911 ± 0.143 g/cm2, respectively.
According to the BMD values of these patients, 50% had oste-
openia and 20% had osteoporosis.
When the two groups were compared, no significant variation
was observed. In particular, the BMD levels were similar at the
femoral neck and at the spine between the groups (Table 1).
Changes in bone mineral density and markers of bone 
turnover at 1 year
In the control group, after 1 year of follow up femoral neck
BMD decreased from 0.797 ± 0.162 g/cm2 to 0.770 ± 0.162
g/cm2 (-2.5%; P < 0.001; Table 2). Similarly, lumbar BMD
decreased from 0.896 ± 0.142 g/cm2 to 0.861 ± 0.142 g/cm2
(-3.9%; P < 0.001). Regarding markers of bone turnover, the
osteocalcin and CTX-I levels remained the same at baseline
and after 1 year. The same stability was observed for 25-OHD
and PTH levels.
In the infliximab group, femoral and lumbar BMD values exhib-
ited no change between baseline and 1 year. The femoral neck
BMD remained stable, being 0.807 ± 0.156 g/cm2 at baseline
and 0.809 ± 0.151 g/cm2 at 1 year (+0.2%; not significant).
The lumbar BMD was also stable, being 0.930 ± 0.142 g/cm2
at baseline and 0.928 ± 0.136 g/cm2 at 1 year (-0.2%; not
significant). Regarding markers of bone turnover, the osteocal-
cin and CTX-I levels did not change significantly between
baseline and 1 year.
Effect of infliximab on bone mineral density values over 
1 year
Various factors are known to influence BMD, including age,
sex, menopause status and steroid use. In order to examine
the specific effect of infliximab within the context of these pos-
sible confounding factors, various linear regression models
were used (Table 3). A direct effect of infliximab in a simple
model was observed, leading to an increase in BMD values of
0.029 g/cm2 (P = 0.001) at the femoral neck and 0.037 g/cm2
(P = 0.001) at the lumbar spine (model 1). The effects of inf-
liximab on BMD remained after stratification for male sex and
age (model 2). After stratification for male sex, age and steroid
use, the effect of infliximab on BMD values at the lumbar spine
remained (0.033 g/cm2; P = 0.001), although the effect was
Table 1
Clinical, biological and densitometry data at baseline
Parameter Whole population Infliximab (n = 90) No infliximab (n = 99) P
Age 52.5 ± 14.2 50.9 ± 11.8 53.9 ± 15.9 NS
Women (n [%]) 152 (80) 74 (82) 78 (79) NS
Disease duration (years) 10.6 ± 9.0 10.2 ± 9.1 10.9 ± 8.9 NS
Patients on steroids (n [%]) 118 (62) 56 (62) 62 (63) NS
Mean dose steroids (mg/day) 5.30 ± 5.79 5.40 ± 5.75 5.26 ± 5.83 NS
DAS28 score 5.17 ± 1.07 5.37 ± 0.94 5.00 ± 1.15 NS
Patients on biphosphonates (n [%]) 35 (19) 15 (17) 20 (20) NS
Calcaemia (mmol/l) 2.28 ± 0.13 2.32 ± 0.12 2.24 ± 0.12 NS
Alkaline phosphatase (U/l) 74.6 ± 25.6 77.5 ± 29.5 72.0 ± 21.2 NS
Osteocalcin (ng/ml) 19.9 ± 11.8 18.4 ± 9.7 21.2 ± 13.4 NS
CTX-I (pg/ml) 446 ± 307 482 ± 386 418 ± 227 NS
Parathyroid hormone (pg/ml) 30.5 ± 17.6 28.7 ± 15.4 32.0 ± 19.1 NS
25-hydroxycholecalciferol (ng/ml) 19.7 ± 10.3 18.2 ± 10.1 21.2 ± 10.4 NS
Femoral neck BMD (g/cm2) 0.801 ± 0.159 0.807 ± 0.156 0.797 ± 0.162 NS
Lumbar BMD (g/cm2) 0.911 ± 0.143 0.930 ± 0.142 0.896 ± 0.142 NS
Patients with neck osteopenia (n [%]) 96 (51) 47 (52) 49 (50) NS
Patients with lumbar osteopenia (n [%]) 93 (49) 40 (45) 53 (54) NS
Patients with neck osteoporosis (n [%]) 37 (20) 18 (20) 19 (19) NS
Patients with lumbar osteoporosis (n [%]) 37 (19) 15 (17) 23 (23) NS
Values are shown for each parameter at baseline, expressed as mean ± standard deviation or n (%). Data for both groups (case and control) were 
compared using the unpaired Student's t-test for continuous variables and the χ2 test for discrete variables. BMD, bone mineral density; CTX-I, C-
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not significant at the femoral neck (0.020 g/cm2; P = 0.03;
model 3). Stratification for male sex, age, menopause status,
steroid status and DAS28 level (model 4) did not change the
association of infliximab treatment with increased BMD at the
lumbar spine (0.034 g/cm2; P = 0.001) and at the femoral
neck (0.023 g/cm2; P = 0.01). When we added biphospho-
nate status to the model (model 5), similar effects of infliximab
on BMD were observed at the lumbar spine (0.035 g/cm2; P
= 0.001) and at the femoral neck (0.023 g/cm2; P = 0.02). Inf-
liximab was found to have similar effects on BMD at the lumbar
spine (0.041 g/cm2;  P  = 0.001) and at the femoral neck
(0.028 g/cm2; P = 0.002) when baseline BMD values were
taken into account (Model 6).
Relation to infliximab response
Sixty-four patients (64%) receiving infliximab were classified
as good responders, as defined by an improvement of at least
1.2 in DAS28 score at 1 year. At baseline, no significant differ-
ence was observed in BMD at the two sites between clinical
responders and nonresponders. The change in lumbar spine
BMD was +0.4% (0.890 ± 0.163 g/cm2 at baseline and 0.894
± 0.154 g/cm2 1 year later) for nonresponders and -0.8%
(0.955 ± 0.141 g/cm2 at baseline and 0.947 ± 0.127 g/cm2 1
year later) for responders. Similarly, the change in BMD at the
femoral neck was +2.0% (0.765 ± 0.157 g/cm2 at baseline
and 0.780 ± 0.174 g/cm2 1 year later) in the nonresponders
and -0.4% (0.840 ± 0.142 g/cm2 at baseline and 0.836 ±
0.141 g/cm2 1 year later) in responders (Figure 1). Accord-
ingly, there was no significant difference in BMD between
responders and nonresponders. These results indicate that
there was bone protection in patients classified as nonre-
sponders, in whom a positive response in terms of RA signs
and symptoms could not be demonstrated.
Correlation between markers of bone turnover and 
clinical parameters or bone mineral density values
On looking for correlation between bone markers and clinical
parameters in the whole population (control and infliximab
groups), some interesting correlations were observed. Nega-
tive correlations were observed between age and BMD at the
lumbar spine and femoral neck (r = -0.279, P < 0.001 and r =
-0.398, P < 0.001, respectively). Steroid dose correlated with
lower levels of bone formation markers, reflected by osteocal-
cin level (r = -0.322; P < 0.001). Similarly, when we looked for
correlation between BMD values and markers of bone turno-
ver in the whole population, we observed a negative correla-
tion between osteocalcin levels and lumbar spine and femoral
neck BMD (r = -0.301, P < 0.001 and r = -0.193, P < 0.001,
respectively). However, we observed no association between
changes in bone markers and changes in BMD values.
Discussion
To our knowledge, this appears to be the first study to examine
the effect of infliximab on BMD in RA patients and to compare
the findings with those in a control group. The major finding of
our study is that bone loss was prevented in RA patients
treated with infliximab. This protective effect was also
observed in patients who did not exhibit a clinical response.
Table 2
Bone markers and densitometry data at baseline and 1 year later
Group Baseline 1 year P
Control
Osteocalcin 21.2 ± 13.4 20.7 ± 11.5 NS
CTX-I 418 ± 227 391 ± 259 NS
Parathyroid hormone 32.0 ± 19.1 36.0 ± 19.7 NS
25-hydroxycholecalciferol 21.2 ± 10.4 22.8 ± 10.5 NS
Femoral neck BMD 0.797 ± 0.162 0.770 ± 0.162 <0.001
Lumbar BMD 0.896 ± 0.142 0.861 ± 0.142 <0.001
Infliximab
Osteocalcin 18.4 ± 9.7 15.7 ± 10.9 NS
CTX-I 482 ± 386 452 ± 271 NS
Parathyroid hormone 29.1 ± 15.4 32.6 ± 15.5 NS
25-hydroxycholecalciferol 17.9 ± 10.1 19.6 ± 9.2 NS
Femoral neck BMD 0.807 ± 0.156 0.809 ± 0.151 NS
Lumbar BMD 0.930 ± 0.142 0.928 ± 0.136 NS
Values are shown for each parameter at baseline and at 1 year, expressed as mean ± standard deviation. In each group, data were compared 
using the Student's paired t-test for continuous variables, between baseline and 1 year. BMD, bone mineral density; CTX-I, C-terminal cross-
linking telopeptide of type I collagen.Available online http://arthritis-research.com/content/9/3/R61
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Bone loss in RA patients depends on a number of factors. This
patient population is already at high risk for osteoporosis
because of advanced age, female sex and menopause. In
addition, active disease and extended duration of disease also
have indirect adverse effects on bone, combined with the use
of steroids and even methotrexate. Selecting an appropriate
control group for such a study is difficult. Even a planned pla-
cebo-controlled trial is imperfect, because the application of
exclusion criteria represents a difference from the real world
situation. Accordingly, we opted to use historical controls
because infliximab is now on the market, and it would be
unethical not to use and even to withhold infliximab treatment
from RA patients with active disease. We regarded the optimal
situation to be one in which the only major difference between
groups would be receipt/nonreceipt of infliximab. Outside the
setting of a formal clinical trial, the best available option was to
select a population of RA patients followed at the same insti-
tution at a time before the advent of anti-TNF-α treatment.
We first verified that our populations at baseline were repre-
sentative. We were able to confirm the presence of the typical
correlations of age and disease duration with lower BMD. Sim-
Table 3
Analysis of the effect of infliximab on BMD using different linear regression models
Models Cofactors Femoral neck BMD Lumbar BMD
BMD variation P BMD variation P
1 Infliximab 0.027 0.001 0.030 0.001
2 Infliximab 0.027 0.001 0.031 0.001
Male sex -0.009 0.40 0.008 0.47
Age 0.002 0.56 0.005 0.09
3 Infliximab 0.020 0.03 0.033 0.001
Male sex -0.014 0.22 0.006 0.64
Age 0.001 0.86 0.005 0.15
Patients on steroids -0.012 0.20 -0.001 0.92
4 Infliximab 0.023 0.01 0.034 0.001
Male -0.014 0.22 0.006 0.61
Age -0.001 0.90 -0.001 0.88
Menopause 0.005 0.75 0.022 0.20
Patients on steroids -0.010 0.29 -0.002 0.87
DAS28 -0.008 0.04 -0.006 0.17
5 Infliximab 0.023 0.02 0.035 0.001
Male -0.015 0.20 0.007 0.58
Age -0.001 0.85 0.000 0.95
Menopause 0.006 0.70 0.020 0.25
Patients on steroids -0.009 0.37 -0.004 0.65
DAS28 -0.008 0.05 -0.006 0.15
Patients on 
biphosphonates
-0.012 0.29 0.022 0.07
6 Infliximab 0.028 0.002 0.041 0.001
Male -0.007 0.53 0.010 0.39
Age -0.002 0.61 0.002 0.63
Patients on steroids -0.008 0.35 -0.001 0.91
DAS28 -0.007 0.06 -0.007 0.10
Baseline BMD values -0.042 0.16 -0.080 0.01
All 189 patients were included in several analysis of covariance models for bone mineral density (BMD) variations (final values minus initial values) 
to analyze the effect of cofactors (continuous variables and discrete variables) on that of infliximab. DAS, Disease Activity Score.Arthritis Research & Therapy    Vol 9 No 3    Marotte et al.
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ilarly, patients receiving steroids exhibited lower levels of mark-
ers of bone formation markers. Our findings of these usual
correlations provide validation of the data at baseline.
In the study, we were unable to demonstrate an increase in
BMD with infliximab, as was recently observed in smaller stud-
ies conducted without a control group in RA patients (n = 26)
[9] and in patients with spondylarthropathy (n = 29) [14] and
Crohn's disease (n = 46) [15]. Recently, however, infliximab
was found to prevent deterioration in BMD at spine and hip,
but not in hands in RA patients [10]. Once again, however, no
control group was employed.
Regarding markers of bone turnover, no significant changes
were observed over the 1 year of follow up. However, negative
correlations between BMD and osteocalcin in this population
contrast with the physiological association between osteocal-
cin and bone formation. The findings suggest a defect in bone
formation that may be explained, in part, by systemic inflamma-
tion. Indeed, in one of our previous studies [16], uncoupling
between bone destruction and formation was observed in
destructive RA. Such uncoupling was not observed in benign
RA. It now appears that TNF-a inhibition may restore this cou-
pling of destruction with formation.
Early changes in bone markers were previously observed in a
study conducted in 68 RA patients who were treated with inf-
liximab [17]. Bone formation markers (osteocalcin and N-
propeptide of type I procollagen) increased quickly at weeks 2
and 6 after initiation of infliximab treatment. The long-term
effect of infliximab at 1 year was recently described in a small
population of patients with RA (n = 26) [9], manifesting as a
persistent increase in osteocalcin (reflecting bone formation)
and a persistent decrease in CTX-I (reflecting bone resorp-
tion). However, in 70 patients with RA who were treated with
infliximab plus methotrexate, a decrease was observed only in
bone resorption markers (urinary excretion of N-telopeptide of
type I collagen and deoxypyridinoline) [18]. No effect on serum
bone alkaline phosphatase, a marker of bone formation, was
observed. In patients with spondylarthropathy treated with inf-
liximab, an early decrease in CTX-I was observed at 3 months
(-50%; P = 0.005). However, CTX-I levels further increased at
1 year as compared with baseline [19]. In another study, inflix-
imab therapy had a lesser effect on serum osteoprotegerin and
soluble receptor activator of nuclear factor-kB ligand
(sRANKL) in RA patients [20]. Recently, decreases in CTX-I
and sRANKL were observed over 1 year of infliximab treatment
[10]. However, in none of these studies was a control group
included, preventing a true estimation of the effect of anti-TNF-
a treatment on bone. In this study, an early and transient effect
on markers of bone turnover (increased bone formation and
decreased bone resorption) was found to be associated with
the effect on BMD at 1 year, as was demonstrated in a previ-
ous study for CTX-I [10].
It appears that blocking TNF-a is protective with respect to
bone mass, and this effect of infliximab on BMD was inde-
pendent of use of biphosphonates and other putative covari-
ates. That this protective effect was also observed in clinical
nonresponders to infliximab is in accordance with the findings
of a recent study [8] that demonstrated protective effects on
joint destruction in the absence of clinical response. Similarly,
studies conducted in postmenopausal women [4] identified an
association between activated status in blood mononuclear
cells/monocytes and increased production of proinflammatory
cytokines. This increase was sensitive to oestrogen
replacement.
Conclusion
This study indicates that TNF-a inhibition controls bone loss
related to generalized osteoporosis within the context of RA.
This is another reason to differentiate local joint inflammation
from juxta-articular bone destruction.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The initial draft of the report was written by HM and PM.
Patients were recruited and clinical parameters provided by
Figure 1
Changes in BMD over 1 year Changes in BMD over 1 year. Changes over 1 year in bone mineral 
density (BMD), for methotrexate (control) and infliximab groups, are 
represented in percentages at (a) the femoral neck and (b) lumbar 
spine. For the infliximab group, changes in BMD are also separated 
according to the clinical response, defined by an improvement of at 
least 1.2 in Disease Activity Score (DAS)28 score over 1 year. NS, not 
significant.Available online http://arthritis-research.com/content/9/3/R61
Page 7 of 7
(page number not for citation purposes)
HM, BP-P, LG, PG, CA and PM. The paper was written by HM
and PM.
Acknowledgements
We thank S Arnaud for bone marker measurements, S Giraud and C 
Quillon for BMD measurements, and R Ecochard for studies with linear 
regression models. This work was supported in part by grants from the 
Hospices Civils of Lyon, the Region Rhône-Alpes and the PHRC.
References
1. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, van Riel PL,
Pasker-de Jong PC, Laan RF: Change in bone mineral density in
patients with rheumatoid arthritis during the first decade of
the disease.  Arthritis Rheum 2001, 44:1254-1260.
2. Gough AK, Lilley J, Eyre S, Holder RL, Emery P: Generalised bone
loss in patients with early rheumatoid arthritis.  Lancet 1994,
344:23-27.
3. Laan RF, Buijs WC, Verbeek AL, Draad MP, Corstens FH, van de
Putte LB, van Riel PL: Bone mineral density in patients with
recent onset rheumatoid arthritis: influence of disease activity
and functional capacity.  Ann Rheum Dis 1993, 52:21-26.
4. Pacifici R, Avioli LV: The effect of natural and surgical meno-
pause on the secretion of cytokines from human blood
monocytes.  Osteoporos Int 1993, 3(Suppl 1):106-107.
5. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P,
Garcia I: Transgenic mice expressing soluble tumor necrosis
factor-receptor are protected against bone loss caused by
estrogen deficiency.  J Clin Invest 1997, 99:1699-1703.
6. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR:
Stimulation of bone resorption and inhibition of bone forma-
tion in vitro by human tumour necrosis factors.  Nature 1986,
319:516-518.
7. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M,
Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab
(chimeric anti-tumour necrosis factor alpha monoclonal anti-
body) versus placebo in rheumatoid arthritis patients receiv-
ing concomitant methotrexate: a randomised phase III trial.
ATTRACT Study Group.  Lancet 1999, 354:1932-1939.
8. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D,
Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group: Evi-
dence of radiographic benefit of treatment with infliximab plus
methotrexate in rheumatoid arthritis patients who had no clin-
ical improvement: a detailed subanalysis of data from the anti-
tumor necrosis factor trial in rheumatoid arthritis with con-
comitant therapy study.  Arthritis Rheum 2005, 52:1020-1030.
9. Lange U, Teichmann J, Muller-Ladner U, Strunk J: Increase in
bone mineral density of patients with rheumatoid arthritis
treated with anti-TNF-alpha antibody: a prospective open-
label pilot study.  Rheumatology (Oxford) 2005, 44:1546-1548.
10. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van
de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF: Evalu-
ation of bone mineral density, bone metabolism, osteoprote-
gerin and RANKL serum levels during treatment with
infliximab in patients with rheumatoid arthritis.  Ann Rheum Dis
2006, 65:1495-1499.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The Amer-
ican Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis.  Arthritis Rheum 1988,
31:315-324.
12. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de
Putte LB, van Riel PL: Development and validation of the Euro-
pean League Against Rheumatism response criteria for rheu-
matoid arthritis. Comparison with the preliminary American
College of Rheumatology and the World Health Organization/
International League Against Rheumatism Criteria.  Arthritis
Rheum 1996, 39:34-40.
13. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD:
Apparent pre- and postmenopausal bone loss evaluated by
DXA at different skeletal sites in women: the OFELY cohort.  J
Bone Miner Res 1997, 12:683-90.
14. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C:
Increase in bone mineral density of patients with spondyloar-
thropathy treated with anti-tumour necrosis factor alpha.  Ann
Rheum Dis 2003, 62:347-349.
15. Bernstein M, Irwin S, Greenberg GR: Maintenance infliximab
treatment is associated with improved bone mineral density in
Crohn's disease.  Am J Gastroenterol 2005, 100:2031-2035.
16. Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P: Uncou-
pling of bone metabolism in rheumatoid arthritis patients with
or without joint destruction: assessment with serum type I col-
lagen breakdown products.  Bone 1999, 24:381-385.
17. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de
Koning MH, Dijkmans BA, Lems WF: Early changes in bone
metabolism in rheumatoid arthritis patients treated with
infliximab.  Arthritis Rheum 2003, 48:2996-2997.
18. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T,
Nagafusa T, Nagano A: The effect of infliximab on bone metab-
olism markers in patients with rheumatoid arthritis.  Rheuma-
tology (Oxford) 2006, 45:761-764.
19. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C: Body
weight, body composition and bone turnover changes in
patients with spondyloarthropathy receiving anti-TNFalpha
treatment.  Ann Rheum Dis 2005, 64:1137-1140.
20. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G,
Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J,
Szechinski J, Kowalczewski J, et al.: High levels of osteoprote-
gerin and soluble receptor activator of nuclear factor kappa B
ligand in serum of rheumatoid arthritis patients and their nor-
malization after anti-tumor necrosis factor alpha treatment.
Arthritis Rheum 2002, 46:1744-1753.